title: Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome.
abstract: A hypercoagulable state and an increased incidence of thromboembolic complications are reported in Cushing's syndrome. The hypercoagulable state is related to an increase in plasma clotting factors, especially Factor VIII and von Willebrand factor complex, and to an impairment of fibrinolytic capacity. Retrospective analysis of postoperative thromboembolic events in a large group of patients with Cushing's syndrome, including 75 patients (group 1) evaluated in the period from 1972-1981 not receiving anticoagulants, and 232 patients (group 2), evaluated in the period from 1982-2000. Patients of group 1 underwent routine hemostatic function, i.e. prothrombin time and activated partial thromboplastine time. Patients of group 2 underwent a thorough investigation as to hemostatic parameters and received prophylactic treatment with heparin and/or warfarin. Patients with Cushing's syndrome showed various abnormalities of hemostatic parameters. A significant correlation between activated partial thromboplastine time and urinary free cortisol was observed. During follow-up, 15 patients (20%; mean follow-up, 9.4 +/- 6.4 yr) of group 1 and 14 (6.0%; mean follow-up, 6.6 +/- 4.2 yr) of group 2 showed thromboembolic complications. Of these patients, eight of group 1 and one of group 2 died. Survival analysis demonstrated a significantly higher morbidity and mortality due to thromboembolic events in group 1, not receiving anticoagulant prevention, than in group 2, treated with anticoagulants in the perioperative period until cure of the disease and normalization of clotting parameters. Cushing's syndrome is associated with a hypercoagulable state. An adequate anticoagulant prophylaxis can reverse this prothrombotic state and avoid postoperative thromboembolic events.
authors.affiliation: Department of Internal Medicine, Division of Endocrinology, University of Ancona, 60100 Ancona, Italy. m.boscaro@ao-umbertoprimo.marche.it
authors.forename: Marco
authors.initials: M
authors.lastname: Boscaro
authors.forename: Nicoletta
authors.initials: N
authors.lastname: Sonino
authors.forename: Alessandro
authors.initials: A
authors.lastname: Scarda
authors.forename: Luisa
authors.initials: L
authors.lastname: Barzon
authors.forename: Francesco
authors.initials: F
authors.lastname: Fallo
authors.forename: Maria T
authors.initials: MT
authors.lastname: Sartori
authors.forename: Giovanni M
authors.initials: GM
authors.lastname: Patrassi
authors.forename: Antonio
authors.initials: A
authors.lastname: Girolami
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000627:therapeutic use*; D002648:Child; D003480:Cushing Syndrome / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013923:Thromboembolism / Q000209:etiology* / Q000401:mortality / Q000517:prevention & control*; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants